AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 596 full-time employees. The company went IPO on 2020-12-11. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. The company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

AbCellera Biologics, Inc. terlibat dalam pengembangan antibodi terapeutik. Perusahaan ini berkantor pusat di Vancouver, British Columbia dan saat ini mempekerjakan 596 karyawan penuh waktu. Perusahaan ini melakukan penawaran umum perdana (IPO) pada 11 Desember 2020. Platformnya mengintegrasikan teknologi, ilmu data, infrastruktur, dan tim multidisipliner untuk memecahkan masalah penemuan antibodi yang menantang. Perusahaan ini fokus pada pengembangan program-program internal dan berkolaborasi dalam program pengembangan obat dengan mitra. Dua program internal pertamanya, ABCL635 dan ABCL575, berada dalam studi pra-klinis tahap akhir. ABCL635 adalah kandidat obat antibodi untuk kondisi metabolik dan endokrin, dan ABCL575 adalah kandidat obat antibodi dengan potensi luas dalam kondisi inflamasi dan penyakit autoimun, serta indikasi awal dalam dermatitis atopik. ABCL575 mengikat OX40L untuk mengganggu sinyal OX40/OX40L, yang merupakan pengatur jalur inflamasi pada dermatitis atopik. Selain ABCL635 dan ABCL575, perusahaan ini mengembangkan lebih dari 20 program penemuan internal.

AbCellera

NVIDIA

Apple

Google

Microsoft

Amazon

Broadcom

Meta Platforms

Taiwan Semiconductor

Tesla

Berkshire Hathaway

Walmart

Eli Lilly

JPMorgan

Visa

Oracle

Exxon Mobil

MasterCard

Johnson & Johnson

Palantir

SPDR S&P500 ETF

ASML

Netflix

Bank of America

AbbVie

Costco

Alibaba

Home Depot

Procter & Gamble

Cisco

Vanguard Total Stock Market ETF

Chevron

Coca-Cola

General Electric

UnitedHealth Group

Wells Fargo

Caterpillar

Morgan Stanley

AstraZeneca

Micron Technology

Goldman Sachs

American Express

Toyota

Novartis

Salesforce

Merck

T-Mobile

Philip Morris

Raytheon Technologies

Royal Bank of Canada

McDonald's

Abbott

Applied Materials

Novo Nordisk

Shopify

Shell

Intuitive Surgical

Invesco QQQ Trust

Citigroup

Lam Research

PepsiCo

Intel

Uber

Disney

QUALCOMM

Intuit

Linde PLC

Blackstone

AT&T

ServiceNow

Amgen

Verizon

NextEra Energy

Charles Schwab

Sony

Booking Holdings

BlackRock

Accenture

Texas Instruments

Danaher

Arista Networks

Banco Santander

Boeing

S&P Global

Toronto-Dominion Bank

Gilead Sciences

Pfizer

Capital One

Adobe

Unilever

Boston Scientific

TotalEnergies

Union Pacific

Lowe's

Analog Devices

AbCellera Stock

About AbCellera

Key Statistics